- Sudden Death Related to Toxicity in a Patient on Capecitabine and Irinotecan Plus Bevacizumab Intake: Pharmacogenetic Implications
[作者:Dahan, L; Ciccolini, J; Evrard, A; Mbatchi, L; Tibbitts, J; Ries, P; Norguet, E; Mercier, C; Iliadis, A; Ouafik, L; Lacarelle, B; Seitz, JF,期刊:Journal of clinical oncology, 页码:E41-E44 , 文章类型: Article,,卷期:2012年30-4]
-
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
[作者:Sperduto, PW; Kased, N; Roberge, D; Xu, ZY; Shanley, R; Luo, XH; Sneed, PK; Chao, ST; Weil, RJ; Suh, J; Bhatt, A; Jensen, AW; Brown, PD; Shih, HA; Kirkpatrick, J; Gaspar, LE; Fiveash, JB; Chiang, V; Knisely, JPS; Sperduto, CM; Lin, N; Mehta, M,期刊:Journal of clinical oncology, 页码:419-425 , 文章类型: Article,,卷期:2012年30-4]
- Purpose Our group has previously published the Graded Prognostic Assessment (GPA), a prognostic index for patients with brain metastases. Updates have been published with refinements to create diagnosis-specific Graded P...
- Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft
[作者:Morelli, MP; Calvo, E; Ordonez, E; Wick, MJ; Viqueira, BR; Lopez-Casas, PP; Bruckheimer, E; Calles-Blanco, A; Sidransky, D; Hidalgo, M,期刊:Journal of clinical oncology, 页码:E45-E48 , 文章类型: Article,,卷期:2012年30-4]
-
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer
[作者:Su, KY; Chen, HY; Li, KC; Kuo, ML; Yang, JCH; Chan, WK; Ho, BC; Chang, GC; Shih, JY; Yu, SL; Yang, PC,期刊:Journal of clinical oncology, 页码:433-440 , 文章类型: Article,,卷期:2012年30-4]
- Purpose Patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations have excellent response to EGFR tyrosine kinase inhibitors (TKIs), but T790M mutation accounts fo...
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
[作者:Karlan, BY; Oza, AM; Richardson, GE; Provencher, DM; Hansen, VL; Buck, M; Chambers, SK; Ghatage, P; Pippitt, CH; Brown, JV; Covens, A; Nagarkar, RV; Davy, M; Leath, CA; Nguyen, H; Stepan, DE; Weinreich, DM; Tassoudji, M; Sun, YN; Vergote, IB,期刊:Journal of clinical oncology, 页码:362-371 , 文章类型: Article,,卷期:2012年30-4]
- Purpose To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes the interaction between the Tie2 receptor and angiopoietin-1/2, plus weekly paclitaxel in patients w...
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
[作者:Kaye, SB; Lubinski, J; Matulonis, U; Ang, JE; Gourley, C; Karlan, BY; Amnon, A; Bell-McGuinn, KM; Chen, LM; Friedlander, M; Safra, T; Vergote, I; Wickens, M; Lowe, ES; Carmichael, J; Kaufman, B,期刊:Journal of clinical oncology, 页码:372-379 , 文章类型: Article,,卷期:2012年30-4]
- Purpose Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy in nonrandomized phase II tri...
- Distribution of Coronary Artery Stenosis After Radiation for Breast Cancer
[作者:Nilsson, G; Holmberg, L; Garmo, H; Duvernoy, O; Sjogren, I; Lagerqvist, B; Blomqvist, C,期刊:Journal of clinical oncology, 页码:380-386 , 文章类型: Article,,卷期:2012年30-4]
- Purpose To study distribution of coronary artery stenosis among patients with breast cancer (BC) and to assess correlation between radiotherapy (RT) and location of stenosis. Patients and Methods A Swedish BC cohort diag...
|